BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
Elizabeth Dudnik(Rabin Medical Center), Jair Bar(Tel Aviv University), Damien Urban(Tel Aviv University), Laila C. Roisman(Shaare Zedek Medical Center), Nir Peled(Shaare Zedek Medical Center), Noa Popovits‐Hadari(Carmel Medical Center), Tzippy Shochat(Rabin Medical Center), Alona Zer(Rambam Health Care Campus), Natalie Maimon Rabinovich(Meir Medical Center), Abed Agbarya(Technion – Israel Institute of Technology), Amir Onn(Tel Aviv University), Moshe Mishaeli(Meir Medical Center), Aaron M. Allen(Tel Aviv University), Mira Wollner(Technion – Israel Institute of Technology), Ofer Rotem(Rabin Medical Center), S. Keren(Carmel Medical Center), Teodor Kuznetsov(Sheba Medical Center), Mor Moskovitz(Rambam Health Care Campus), Hovav Nechushtan(University Medical Center)
Cited by 220
Related Papers
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642